Fixed Drug Eruption (FDE)

01Pathophysiology

Fixed drug eruption is a type IV hypersensitivity reaction that stands out among drug reactions because of its hallmark feature: it recurs at the exact same cutaneous site every time the patient is re-exposed to the offending agent. Understanding the immunologic basis of this phenomenon is central to recognizing it on an exam vignette.

On initial exposure to the culprit drug, antigen-presenting cells in the skin process drug-related antigens and activate CD8+ cytotoxic T lymphocytes. These T cells migrate to the epidermis and, after the acute episode resolves, a population of CD8+ tissue-resident memory T cells (TRM cells) remains behind in the skin at the site of the original reaction. These TRM cells express CD69 and CD103, surface markers that anchor them to the local tissue. They do not circulate; they stay put at that exact location indefinitely.

Upon re-exposure to the same drug, the TRM cells are rapidly reactivated. They release interferon-gamma, TNF-alpha, perforin, and granzyme B, which cause direct keratinocyte apoptosis and epidermal damage. This is the mechanism behind the interface dermatitis seen on biopsy. The dermal melanophages (macrophages that have engulfed melanin from damaged basal keratinocytes) are responsible for the characteristic residual hyperpigmentation, a finding called pigment incontinence. This explains why the dark patch persists long after the acute inflammation has resolved.

The reason the lesion appears at the same site is entirely explained by the fixed anatomic residence of TRM cells. The rest of the skin lacks these primed cells, so it remains unaffected. With each subsequent exposure, the reaction tends to be faster in onset (sometimes within 30 minutes to 2 hours, compared to 1 to 2 weeks on the first exposure) and may recruit additional new sites, though the original site will always be involved.

Common offending drugs to memorize include sulfonamides (trimethoprim-sulfamethoxazole), NSAIDs (naproxen, ibuprofen), tetracyclines, barbiturates, phenytoin, metronidazole, and oral contraceptives. Trimethoprim-sulfamethoxazole and NSAIDs are the most frequently tested culprits.

02Classification and Clinical Manifestation

The classic presentation tested in vignettes is a patient who develops a solitary, round, well-demarcated, dusky-red to violaceous patch within hours of taking a medication. The lesion may be edematous and mildly painful or pruritic. On subsequent episodes, the vignette may describe that the patient has a residual dark patch in the same location that "flares up" whenever they take the same drug. The favored anatomical sites (lips, genitalia, dorsal hands) appear frequently in exam questions.

03Diagnostic Workup

Fixed drug eruption is primarily a clinical diagnosis. The single most important diagnostic maneuver is obtaining a detailed drug history with attention to the temporal relationship between medication exposure and the onset of the lesion. If the patient reports that the same patch appears in the same location each time they take a certain medication, the diagnosis is essentially secured.

When the history is ambiguous or the presentation is atypical, a skin biopsy is the best initial test. The hallmark histopathologic findings include interface dermatitis (lymphocytes obscuring the dermoepidermal junction), scattered necrotic keratinocytes throughout the epidermis, and dermal melanophages indicating pigment incontinence. A perivascular mixed inflammatory infiltrate with eosinophils is also commonly seen. In older, quiescent lesions, the biopsy may predominantly show melanophages with minimal inflammation.

Patch testing can be performed by applying the suspected drug directly to the site of a previous lesion. A positive reaction at the lesional site (but not at uninvolved control skin) supports the diagnosis and helps identify the offending agent. However, sensitivity is variable and depends on the drug tested. Patch testing is most reliable for NSAIDs and trimethoprim-sulfamethoxazole.

The oral provocation test is the gold standard for confirming the diagnosis and identifying the causative drug. It involves administering a controlled dose of the suspected medication and monitoring for recurrence at the known site. Because of the risk of triggering a severe reaction (particularly generalized bullous FDE), this test is performed only when identification of the drug is critical and no safer alternative exists. On the exam, the oral provocation test is more likely to appear as an answer choice in a question asking for the "most accurate test," while the clinical history plus biopsy combination is the practical diagnostic pathway.

04Management and Treatment

The next best step in any exam question involving fixed drug eruption is discontinuing the offending drug. This is always the first and most critical action. Without drug withdrawal, the lesion will persist and may worsen.

For the classic presentation with a solitary painful or pruritic plaque, topical corticosteroids are sufficient. A medium-potency agent such as triamcinolone acetonide 0.1% cream applied twice daily for 7 to 14 days is standard. For lesions on thinner skin (genitalia, face), a lower-potency agent like hydrocortisone 1% should be substituted to avoid skin atrophy.

If the lesion is bullous, local wound care with cool compresses and non-adherent dressings should be initiated. Ruptured bullae should be treated as superficial wounds to prevent secondary bacterial infection.

In the uncommon scenario of generalized bullous FDE with widespread skin involvement, management parallels that of Stevens-Johnson syndrome. Hospitalization may be necessary. A short course of systemic corticosteroids (prednisone 0.5 to 1 mg/kg/day) with a taper over 1 to 2 weeks can be considered, although this remains debated. Supportive measures include fluid resuscitation, pain control, and meticulous wound care.

The long-term management cornerstone is strict avoidance of the culprit medication. Patients should also be counseled about structurally related drugs that may cross-react. For example, a patient who develops FDE from trimethoprim-sulfamethoxazole should avoid all sulfonamide antibiotics. The offending drug should be documented as an allergy in all medical records and the patient should carry this information at all times.

A key exam point: the hyperpigmentation may take months to years to fade, even after complete drug avoidance. This is a normal part of the natural history and does not indicate ongoing disease activity or treatment failure.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common trap on fixed drug eruption questions is the failure to recognize that the lesion recurs at the same anatomical site. Vignettes will often embed this clue subtly, describing a patient with a "persistent dark mark" in a certain area that becomes inflamed each time a medication is used. Students who do not link the recurrence to the fixed nature of the eruption may be drawn toward erythema multiforme or allergic contact dermatitis.

A second frequently tested pitfall is the generalized bullous variant. When the question describes widespread bullous lesions after drug exposure, students instinctively select Stevens-Johnson syndrome or toxic epidermal necrolysis. The discriminating feature is that generalized bullous FDE typically spares the mucous membranes and the patient often has a history of smaller lesions at those same sites on prior drug exposures. If the vignette mentions absent mucosal involvement or prior episodes in the same locations, FDE is the answer.

Another common error involves genital lesions. Because fixed drug eruption has a predilection for the genitalia, questions may construct a scenario that mimics recurrent genital herpes. The key distinguishing detail is morphology: FDE produces a single, well-demarcated, dusky plaque, while herpes simplex presents with grouped vesicles on an erythematous base. If the vignette describes a solitary genital plaque (not vesicles) that recurs with medication use rather than with stress or illness, FDE is the correct diagnosis.

The core competency being tested is your ability to identify the signature pattern of recurrence at the same site following drug re-exposure, to distinguish this condition from its closest mimics by paying attention to lesion morphology and mucosal involvement, and to recognize that the next best step in management is always discontinuing the offending drug.